These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3818022)

  • 1. Platelet activating factor vasoconstriction of dog kidney. Inhibition by alprazolam.
    Baer PG; Cagen LM
    Hypertension; 1987 Mar; 9(3):253-60. PubMed ID: 3818022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary vascular response to platelet-activating factor in awake sheep and the role of cyclooxygenase metabolites.
    Burhop KE; van der Zee H; Bizios R; Kaplan JE; Malik AB
    Am Rev Respir Dis; 1986 Sep; 134(3):548-54. PubMed ID: 3752711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide mediates the inhibitory action of platelet-activating factor on angiotensin II-induced renal vasoconstriction, in vivo.
    Handa RK; Strandhoy JW
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1486-91. PubMed ID: 8667214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition by bradykinin of the vascular action of angiotensin II in the dog kidney.
    Susić H; Nasjletti A; Malik KU
    J Pharmacol Exp Ther; 1981 Jul; 218(1):103-7. PubMed ID: 6165819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of vasoconstrictor responses by platelet-activating factor in rat kidney.
    Handa RK; Strandhoy JW; Buckalew VM
    Am J Physiol; 1991 Jul; 261(1 Pt 2):F108-16. PubMed ID: 1907104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation by arachidonic acid of the effect of vasoconstrictor stimuli in the canine kidney.
    Susić H; Malik KU
    J Pharmacol Exp Ther; 1981 Nov; 219(2):377-82. PubMed ID: 6793715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors.
    Apprill P; Schmitz JM; Campbell WB; Tilton G; Ashton J; Raheja S; Buja LM; Willerson JT
    Circulation; 1985 Aug; 72(2):397-405. PubMed ID: 2988822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constriction of canine coronary arteries by platelet activating factor after brief ischemia.
    Kim YD; Danchak RM; Heim KF; Lees DE; Myers AK
    Prostaglandins; 1993 Sep; 46(3):269-76. PubMed ID: 8234834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of bradykinin of the vascular effects of pressor hormones in the canine kidney: relationship to prostaglandins.
    Susić H; Nasjletti A; Malik KU
    Clin Sci (Lond); 1980 Dec; 59 Suppl 6():145s-148s. PubMed ID: 7449252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cardiac and hemodynamic effects of platelet-activating factor-acether and leukotriene D4 in anesthetized dogs.
    Fiedler VB; Mardin M; Abram TS
    Basic Res Cardiol; 1987; 82(2):197-208. PubMed ID: 3606544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Nitric oxide in the renal and systemic vasodilatory responses to platelet-activating factor in the rat, in vivo.
    Handa RK; Strandhoy JW; Handa SE
    Kidney Blood Press Res; 2003; 26(3):165-75. PubMed ID: 12886044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of platelet activating factor in the pulmonary circulation: an investigation using a novel isotopic system in rabbit isolated lung.
    Seale JP; Nourshargh S; Hellewell PG; Williams TJ
    Br J Pharmacol; 1991 Sep; 104(1):251-7. PubMed ID: 1786514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of platelet-activating factor induced renal hemodynamic and tubular dysfunctions with L-655,240, a new thromboxane-prostaglandin endoperoxide antagonist.
    Hébert RL; Sirois P; Plante GE
    Can J Physiol Pharmacol; 1989 Apr; 67(4):304-8. PubMed ID: 2758373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasorelaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat.
    Handa RK; Strandhoy JW; Buckalew VM
    Life Sci; 1991; 49(10):747-52. PubMed ID: 1875784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-activating factor increases lung vascular permeability to protein.
    Burhop KE; Garcia JG; Selig WM; Lo SK; van der Zee H; Kaplan JE; Malik AB
    J Appl Physiol (1985); 1986 Dec; 61(6):2210-7. PubMed ID: 3804927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triazolobenzodiazepines competitively inhibit the binding of platelet activating factor (PAF) to human platelets.
    Chesney CM; Pifer DD; Cagen LM
    Biochem Biophys Res Commun; 1987 Apr; 144(1):359-66. PubMed ID: 3579913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of adrenergic mediation of agonist response to [Sar1,Ala8]angiotensin II in conscious normotensive and hypertensive dogs.
    Zimmerman BG
    Clin Sci (Lond); 1979 Jul; 57(1):71-81. PubMed ID: 38941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms mediating canine renal vasoconstriction induced by nicotine infusion.
    Hock CE; Passmore JC
    Life Sci; 1985 Nov; 37(21):1997-2003. PubMed ID: 2999537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAF increases hepatic vascular resistance and glycogenolysis in vivo.
    Hines KL; Braillon A; Fisher RA
    Am J Physiol; 1991 Mar; 260(3 Pt 1):G471-80. PubMed ID: 1848410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.
    Noguchi K; Matsuzaki T; Shiroma N; Ojiri Y; Sakanashi M
    Br J Pharmacol; 1996 Jun; 118(4):941-50. PubMed ID: 8799566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.